Table 1. Summary of clinical information, tumor cell yield and intra-cranial tumor formation of PLGG tumors.
| No. | Tumor ID | Age, Gender | Dx, WHO Grade | Tumor cell number(x 106) | Site of injection | Tumor formation in mouse brains | ||
|---|---|---|---|---|---|---|---|---|
| Total | Injected/mouse | Total | With Tumor | |||||
| 1 | ST-1267¶ | 1 y, M | PA, I | 1 | 0.1 | ICb | 5 | 0 |
| 2 | ST-1342¶ | 3 y, F | PA, I | 1.8 | 0.1 | ICb | 2 | 0 |
| 3 | ST-1610¶ | 15 y, M | PA, I | 1 | 0.1 | ICb | 5 | 0 |
| 4 | ST-1823 | 11 y, M | PA, I | 0.38 | 0.1 | ICb | 3 | 0 |
| 5 | ST-1828 | 8 y, M | PA, I | 0.33 | 0.1 | ICb | 3 | 0 |
| 6 | ST-2076 | 8 y, M | PA, I | 1.05 | 0.1 | ICb | 5 | 0 |
| 7 | ST-2109* | 4 y, F | PA, I | 2.68 | 0.16 | ICb | 10 | 0 |
| 8 | ST-2354*¶ | 6 y, M | PA, I | 3.6 | 0.25 | IC | 8 | 0 |
| 9 | ST-2431* | 4 y, F | PA, I | 0.72 | 0.1 | IC | 5 | 0 |
| 10 | ST-2446*¶ | 1 y, M | PA, I | 1.76 | 0.085 | ICb | 3 | 0 |
| 11 | ST-2794*¶ | 5 y, F | PA, I | 1.12 | 0.16 | ICb | 3 | 0 |
| 12 | ST-2879*¶ | 12y, M | PA, I | 1.1 | 0.1 | ICb | 5 | 0 |
| 13 | ST-2990¶ | 11 y, F | PA, I | 1.54 | 0.2 | ICb | 5 | 0 |
| 14 | ST-3016 | 9 y, M | PA, I | 0.45 | 0.12 | ICb | 3 | 0 |
| 15 | ST-3278* | 10 y, F | PA, I | 2 | 0.15 | ICb | 5 | 0 |
| 16 | ST-3526*¶ | 9 y, M | PA, I | 4.3 | 0.15 | ICb | 10 | 0 |
| 17 | ST-3580¶ | 13 y, F | PA, I | 1.12 | 0.2 | ICb | 5 | 0 |
| 18 | ST-3593 | 5 y, M | PA, I | 1.55 | 0.15 | ICb | 10 | 0 |
| 19 | ST-3648¶ | 6 y, M | PA, I | 2.7 | 0.28 | IC | 7 | 0 |
| 20 | ST-4109¶ | 4 y, F | PA, I | 2 | 0.2 | ICb | 5 | 0 |
| 21 | ST-4666¶ | 1 y, F | PA, I | 1.85 | 0.15 | ICb | 10 | 0 |
| 22 | ST-1756*¶ | 9 y, M | PA, I | 0.025 | No | |||
| 23 | ST-2270* | 9 y, M | PA, I | 0.1 | No | |||
| 24 | ST-2439* | 8 y, M | PA, I | 0.058 | No | |||
| 25 | ST-2728¶ | 17 y, M | PA, I | 0.03 | No | |||
| 26 | ST-3490 | 13 y, M | PA, I | 0.01 | No | |||
| 27 | ST-3510¶ | 10 y, F | PA, I | 0.05 | No | |||
| 28 | ST-5293¶ | 8 y, F | PA, I | 0.05 | No | |||
| 29 | ST-5336*¶ | 5 y, M | PA, I | 0.4 | No | |||
| 30 | ST-4461 | 11 y, F | AST, II | 0.31 | 0.1 | ICb | 3 | 0 |
| 31 | ST-4388*¶ | 11 y, F | AST, II | 0.03 | No | |||
| 32 | ST-4034¶ | 6 y, F | GG | 0.06 | No | |||
| 33 | ST-2829*¶ | 12 y, M | GG | 0.37 | 0.063 | ICb | 5 | 0 |
| 34 | ST-4524 | 13 y, F | GG | 2.55 | 0.25 | IC | 10 | 0 |
| 35 | ST-4710¶ | 13 y, F | GG | 0.36 | No | |||
| 36 | ST-3635* | 10 y, F | PXA, II | 3.48 | 0.1 | IC | 7 | 2 |
Note: *Tested for neurosphere formation, ¶Analyzed with FCM for CSC markers, Dx= diagnosis, ICb=Intra-cerebellar, IC=Intra-cerebral, PA=Pilocytic astrocytoma, AST=astrocytoma, GG=Ganglioglioma, PXA = Pleomorphic Xanthoastrocytoma